Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease

Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease

Rey Isidto,1 Romina Danguilan,2 Oscar Naidas,3 Russell Vilanueva,2 Mel-Hatra Arakama,2 Layla Marie Paraiso2 1HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2Department of Adult Nephrology, National Kidney and Transplant Institute, Quezon City, M...

Full description

Bibliographic Details
Main Authors:	Isidto R, Danguilan R, Naidas O, Vilanueva R, Arakama MH, Paraiso LM
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-02-01
Series:	International Journal of Nephrology and Renovascular Disease
Subjects:	chronic renal insufficiency diabetic nephropathies safety sodium-glucose transporter 2 inhibitors
Online Access:	https://www.dovepress.com/emerging-role-of-sodiumglucose-co-transporter-2-inhibitors-for-the-tre-peer-reviewed-fulltext-article-IJNRD

Similar Items

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
by: Nam Hoon Kim, et al.
Published: (2022-07-01)

Evaluating the renoprotective effectiveness of sodium-glucose co-transporter 2 inhibitor therapy in patients with chronic kidney disease: A prospective study
by: Karadžić-Ristanović Vidna, et al.
Published: (2024-01-01)

Promising role of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy
by: Samaneh Zandifar, et al.
Published: (2023-06-01)

SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
by: Mariana Silva de Sousa, et al.
Published: (2023-06-01)

Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience
by: Mohammed H Tawhari, et al.
Published: (2023-01-01)

SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease
by: Paulo André Bispo Machado Júnior, et al.
Published: (2024-09-01)

SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
by: Jasna Klen, et al.
Published: (2023-07-01)

Update on Sodium Glucose Cotransporter Type 2 Inhibitors Use in Kidney Transplant Patients
by: Maurizio Salvadori, et al.
Published: (2024-09-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Budget Impact and Cost–Benefit Analyses of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in Thailand
by: Arunmanakul P, et al.
Published: (2025-02-01)

How to delay the progression of chronic kidney disease: focusing on medications
by: Jeesu Min
Published: (2024-06-01)

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin
by: M. M. Batyushin
Published: (2021-04-01)

Concomitant treatment with insulin and sodium–glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score‐matched analysis
by: Masao Toyoda, et al.
Published: (2022-09-01)

Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
by: Elkeraie AF, et al.
Published: (2024-01-01)

Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we “gliflozin” patients with kidney stone disease?
by: Mauricio de Carvalho, et al.
Published: (2024-02-01)

Sodium–Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension
by: Hu Y, et al.
Published: (2024-01-01)

Remission of Proteinuria in a Patient Affected by Crescentic IgA Nephropathy with Rapidly Progressive Glomerulonephritis Treated by Sodium-Glucose Cotransporter-2 Inhibitors: Casual or Causal Relationship?
by: José C. De La Flor Merino, et al.
Published: (2022-10-01)

Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
by: Min-Jia Cao, et al.
Published: (2025-01-01)

The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01)

Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model
by: Amarit Tansawet, et al.
Published: (2024-11-01)

Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
by: Stephen Melnick, et al.
Published: (2018-09-01)

Sodium-glucose co-transporter 2 inhibitors – a review article
by: Marcin Makuch, et al.
Published: (2019-08-01)

Sodium-glucose co-transporter 2 inhibitors – a review article
by: Marcin Makuch, et al.
Published: (2019-08-01)

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes
by: Xie H, et al.
Published: (2024-11-01)

Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice
by: Miho Murashima, et al.
Published: (2022-04-01)

Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01)

Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews
by: Yixuan Fang, et al.
Published: (2024-06-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
by: Anthony T. P. Chan, et al.
Published: (2022-11-01)

The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy
by: Sha Su, et al.
Published: (2023-12-01)

Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights
by: Han-Sang Baek, et al.
Published: (2024-11-01)

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01)

Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
by: Seung Eun Lee, et al.
Published: (2022-07-01)

Renal protective effects of sodium bicarbonate tablets after coronary artery angiography
by: WANG Peng, LIU Anheng, LUO Jianping, SHI Hongpo, GUO Qing
Published: (2023-11-01)

Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
by: In-Young Nho, et al.
Published: (2018-12-01)

Effects of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetic and Non-Diabetic Patients with Advanced Chronic Kidney Disease in Peritoneal Dialysis on Residual Kidney Function: In Real-World Data
by: Esperanza Moral Berrio, et al.
Published: (2024-07-01)

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
by: Keiichi Torimoto, et al.
Published: (2017-08-01)

The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter
by: Diana Sh. Avzaletdinova, et al.
Published: (2021-09-01)

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)